Vantictumab /vænˈtɪktʊmæb/ is a human IgG2 monoclonal antibody designed for the treatment of cancer.
[1] This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with Bayer.
[2] OncoMed was awarded a patent in 2016, which is set to expire in 2029.
[3] In April 2017, Bayer terminated its option to license vantictumab.
[4] It inhibits wnt signalling by targeting the frizzled receptors on cancer cells.